A limitation of this study is that the number of patients from the analyzed Mexican cohorts were restricted to the available samples, being mandatory the validation of RIPOR2 expression as a potential biomarker in a larger cohort of premalignant lesions and cervical cancer samples in a representative proportion of the studied population. The gene discussed is RIPOR2; the disease is cervical cancer.